Conditions: Pancreatic Neoplasms Pancreatic Cancer
Keywords: Pancreatic Neoplasms Pancreatic cancer
Allocation: NA | Intervention model: SINGLE_GROUP
Enrollment: 25
Healthy volunteers: no

Brief summary:
The purpose of this study is to investigate if the investigators can use a specific marker in the pancreatic tumor itself to determine which patients will benefit from receiving combination chemotherapy of gemcitabine and cisplatin after undergoing resection of a pancreatic cancer.

The investigators will also investigate if there is any benefit to receiving both chemotherapy drugs as opposed to only gemcitabine after undergoing complete resection of the tumor.

Detailed description:
The study will specifically be looking at ERCC1 expression in pancreas cancer with regards to its prognostic and predictive value as a biomarker for patients receiving Gem / Cis as adjuvant therapy after resection.

Arms:
arm 1: Single arm study. All patients will receive gemcitabine and cisplatin as adjuvant therapy.

Interventions: intervention 1: Gemcitabine intervention 2: Cisplatin
Intervention descriptions: intervention 1: Standard of care chemotherapy and dosage

Dose - 1000 mg/m²

Schedule - Days 1 and 15; Q 28 days intervention 2: Dose - 50 mg/m²

Schedule - Days 1 and 15; Q 28 days

Protocol document: